v3.20.4
Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Transfers of assets between the fair value measurement levels      
Transfers of assets into Level 3 of the fair value hierarchy $ 0    
Transfers of assets out of Level 3 of the fair value hierarchy 0    
Transfers of liabilities between the fair value measurement levels      
Transfers of liabilities into Level 3 of the fair value hierarchy 0    
Transfers of liabilities out of Level 3 of the fair value hierarchy 0    
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)      
Beginning balance 7,340 $ 4,483 $ 4,534
Additions 225 [1] 0 0
Change in fair value recognized in net earnings (5,753) (3,091) (49)
Payments (321) (234) (100)
Ending balance $ 12,997 $ 7,340 $ 4,483
[1] Additions during the year ended December 31, 2020 represent contingent consideration liabilities assumed in the Allergan acquisition as well as contingent consideration resulting from the Luminera acquisition.